Biltmore Wealth Management LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,807 shares of the biopharmaceutical company’s stock, valued at approximately $707,000. Pfizer accounts for about 0.7% of Biltmore Wealth Management LLC’s holdings, making the stock its 19th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Northstar Group Inc. increased its stake in shares of Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 35 shares during the period. Peregrine Asset Advisers Inc. increased its stake in shares of Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC increased its stake in shares of Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 50 shares during the period. River Wealth Advisors LLC increased its stake in shares of Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 55 shares during the period. Finally, Meridian Wealth Management LLC increased its stake in shares of Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 57 shares during the period. 69.75% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,450 shares of company stock worth $1,065,220. Insiders own 0.06% of the company’s stock.

Several equities analysts have recently issued reports on the company. Morgan Stanley set a $41.00 target price on Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, January 8th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price target on the stock. in a research note on Monday. Jefferies Group set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.89.

Shares of Pfizer Inc. (NYSE:PFE) opened at $36.60 on Wednesday. Pfizer Inc. has a 12 month low of $30.90 and a 12 month high of $37.35. The company has a market capitalization of $218,160.00, a price-to-earnings ratio of 22.45, a PEG ratio of 2.44 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. equities research analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current year.

Pfizer announced that its board has approved a share repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is currently 78.53%.

COPYRIGHT VIOLATION WARNING: “Biltmore Wealth Management LLC Buys New Position in Pfizer Inc. (PFE)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/17/biltmore-wealth-management-llc-buys-new-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.